AstraZeneca to outsource all manufacturing within next decade: report

Share this article:

AstraZeneca said it plans to outsource all of its drug manufacturing within the next 10 years, The Times of London reports.

“Manufacturing for AstraZeneca is not a core activity,” said David Smith, AstraZeneca's EVP of operations, in a report on the newspaper's Web site.

“AstraZeneca is about innovation and brand building … There are lots of people and organizations that can manufacture better than we can,” Smith added.

Smith is reportedly leading a restructuring at the company aimed at cutting costs and improving profitability.

He told The Times that the company's priority would be to outsource all of its manufacturing of active pharmaceutical ingredients.

This year to date, the Anglo-Swedish drugmaker has announced plans to phase out 7,600 staff, nearly 12% of its workforce, to help save the company an estimated $900 million by 2010.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.